Clinical Trial Update: Safety and Efficacy of BARS13 in the Elderly [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of BARS13 in elderly participants with respiratory syncytial virus infections has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• BARS13

Snippet

Sponsor: Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED